Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma - Takeaways - MDSpire

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma

  • By

  • Yingyu Yang

  • Junkai Zhang

  • Zhirun Xie

  • Sirui Zhang

  • May 25, 2026

  • 0 min

Share

  • 1

    ALK-positive lung squamous cell carcinoma (LSCC) has an incidence of less than 1%, making it a rare condition.

  • 2

    Neoadjuvant ensartinib led to a complete pathological response in a case of stage IIIB ALK-positive LSCC.

  • 3

    The patient experienced a rapid partial response after four weeks of ensartinib, followed by successful surgery.

  • 4

    Postoperative examination revealed no tumor cells, indicating a complete pathologic response after treatment.

  • 5

    The study highlights the potential of neoadjuvant ALK inhibitors in treating locally advanced, resectable LSCC.

Original Source(s)

Case report: complete pathologic response to neoadjuvant ensartinib in locally advanced, ALK-positive lung squamous cell carcinoma

  • by Yingyu Yang, Junkai Zhang, Zhirun Xie, Sirui Zhang

  • May 25, 2026

Related Content

PD-1 inhibitor combined with chemoradiotherapy in two cases of ovarian cancer brain metastases: a case report

FEBAIR microsurgical principles in meningiomas and recurrence: a long-term follow-up series

Gastric-type endocervical adenocarcinoma with Peutz-Jeghers syndrome: a case report and literature review